SCHEMBL770083

SCHEMBL770083

COc1ccc(-n2cnc3cc(NCc4ccccc4OC)ccc32)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.71
GAA P10253 4/20 0.71
HPGD P15428 8/20 0.68
ALDH1A1 P00352 8/20 0.68
KDM4E B2RXH2 7/20 0.68
L3MBTL1 Q9Y468 5/20 0.68
TDP1 Q9NUW8 4/20 0.68
LMNA P02545 4/20 0.67
SMN1; SMN2 Q16637 4/20 0.67
NPC1 O15118 3/20 0.67
RAB9A P51151 2/20 0.67
ALOX15 P16050 1/20 0.67
TSHR P16473 1/20 0.67
GPR55 Q9Y2T6 2/20 0.65
KIT P10721 2/20 0.63
FLT3 P36888 2/20 0.63
HTT P42858 2/20 0.58
THRB P10828 1/20 0.57
PKM P14618 1/20 0.57
MEN1 O00255 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13305021 0.92 KIT (0.73) MAPTGAAHPGDALDH1A1KDM4E
SCHEMBL769547 0.91 MAPT (0.71) MAPTGAAHPGDALDH1A1KDM4E
SCHEMBL13304997 0.91 MAPT (0.64) MAPTGAAHPGDALDH1A1KDM4E
SCHEMBL769540 0.88 MAPT (0.73) MAPTGAAHPGDALDH1A1KDM4E
SCHEMBL783951 0.87 MAPT (0.67) MAPTGAAHPGDALDH1A1KDM4E
SCHEMBL783937 0.86 MAPT (0.86) MAPTGAAHPGDALDH1A1KDM4E
SCHEMBL770038 0.84 MAPT (0.72) MAPTGAAHPGDALDH1A1KDM4E
SCHEMBL769090 0.84 KIT (0.77) MAPTGAAHPGDALDH1A1KDM4E
SCHEMBL770287 0.83 KIT (0.82) MAPTGAAHPGDALDH1A1KDM4E
SCHEMBL770130 0.82 MAPT (0.70) MAPTGAAHPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629170-B2 Anti-viral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2014-01-14 US claimed
EP-1988776-B1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES INC (US) 2012-08-08 EP claimed
US-20110172281-A1 Anti-Viral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2011-07-14 US claimed
US-7977365-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2011-07-12 US claimed
EP-2291184-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION Siga Technologies, Inc. (US) 2011-03-09 EP claimed
US-7872037-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2011-01-18 US claimed
WO-2010036399-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2010-04-01 WO claimed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US claimed
EP-1988776-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2008-11-12 EP claimed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US claimed
WO-2007103111-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2007-09-13 WO claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8629170-B2 Anti-viral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2014-01-14 US disclosed
US-8629170-B2 Anti-viral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2014-01-14 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US disclosed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172281-A1 Anti-Viral Drugs for Treatment of Arenavirus Infection GK, GALK1, KLK7 MAPT 923/4885GAA 57/4885HPGD 2860/4885
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection GK, GALK1, GZMB MAPT 1022/4885GAA 70/4885HPGD 2815/4885
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION GK, MAVS, ZC3HAV1 MAPT 1158/4885GAA 29/4885HPGD 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.